Heterologous AstraZeneca and Pfizer vaccines induce strong immune response and T cell reactivity against multiple SARS-CoV-2 variants

Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.